PRKCD and Alzheimer disease: In the AD transgenic mouse line of APPswe/PS1dE9, rottlerin-mediated PKCδ inhibition rescued cognitive deficits while reducing Aβ generation and deposition [10], suggesting that PKCδ may be a potential therapeutic target for AD.